At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT (Autologous Stem-Cell Transplantation)
In Brief
A Phase 2 clinical trial evaluating Lenalidomide for Diffuse Large B-cell Lymphoma. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This phase II multi-institutional trial will explore the safety and efficacy of lenalidomide monotherapy given as maintenance therapy following salvage chemo-immunotherapy in patients with relapsed or refractory chemosensitive diffuse large B-cell lymphoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesItaly
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartMar 2009
Primary CompletionMar 2017
Study CompletionAug 2021
TodayJul 2026
First PostedDec 1, 2008
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2017
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 17.6 years ago
Interventions
Lenalidomidedrug
single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.